Brief: Hls Therapeutics Announces Qtrly Net Loss $0.19 Per Common Share
May 16 (Reuters) - HLS Therapeutics Inc HLS.V :
* HLS THERAPEUTICS ANNOUNCES Q1 2018 FINANCIAL RESULTS
* CASH AND CASH EQUIVALENTS $53.8 MILLION AT END OF Q1
* Q1 REVENUE $13.2 MILLION VERSUS $15.6 MILLION
* QTRLY NET LOSS $0.19 PER COMMON SHARE
Source text for Eikon: ID:nCNWjvdmMa
Further company coverage: HLS.V
(Reuters.Briefs@thomsonreuters.com)
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease